{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:39:09Z","timestamp":1780493949804,"version":"3.54.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T00:00:00Z","timestamp":1317686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1007\/s11910-011-0232-9","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T07:48:14Z","timestamp":1317628094000},"page":"54-61","source":"Crossref","is-referenced-by-count":49,"title":["Update on Toxic Myopathies"],"prefix":"10.1007","volume":"12","author":[{"given":"F. L.","family":"Mastaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,4]]},"reference":[{"key":"232_CR1","unstructured":"Mastaglia FL. Handbook of clinical neurology. Elsevier Science Publishers B. V.; 1992."},{"issue":"5","key":"232_CR2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/WCO.0b013e32830e2774","volume":"21","author":"T Klopstock","year":"2008","unstructured":"Klopstock T. Drug-induced myopathies. Curr Opin Neurol. 2008;21(5):590\u20135.","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"232_CR3","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","volume":"80","author":"MC Dalakas","year":"2009","unstructured":"\u2022 Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009;80(8):832\u20138. This is an excellent review of the pathology and mechanisms of toxic and drug-induced myopathies.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"232_CR4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/WCO.0b013e32833045a0","volume":"22","author":"RW Kuncl","year":"2009","unstructured":"\u2022 Kuncl RW. Agents and mechanisms of toxic myopathy. Curr Opin Neurol. 2009;22(5):506\u201315. This is a comprehensive update on statin and other drug-induced and toxic myopathies.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"232_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","volume":"12","author":"R Valiyil","year":"2010","unstructured":"\u2022 Valiyil R, Christopher-Stine L. Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep. 2010;12(3):213\u201320. This is an excellent review of drug-induced myopathies.","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"232_CR6","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"\u2022 Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757\u201366. This is an important original report of autoantibodies in statin-associated necrotizing myopathy.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"232_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/WCO.0b013e32833c2054","volume":"23","author":"FL Mastaglia","year":"2010","unstructured":"Mastaglia FL. Iatrogenic myopathies. Curr Opin Neurol. 2010;23(5):445\u20139.","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"232_CR8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/BOR.0b013e32833f0fc7","volume":"22","author":"AL Mammen","year":"2010","unstructured":"Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22(6):644\u201350.","journal-title":"Curr Opin Rheumatol"},{"issue":"1\u20133","key":"232_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2009.05.014","volume":"117","author":"AJ Dirks-Naylor","year":"2009","unstructured":"Dirks-Naylor AJ, Griffiths CL. Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol. 2009;117(1\u20133):1\u20137.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"232_CR10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pds.1602","volume":"17","author":"LA Garcia-Rodriguez","year":"2008","unstructured":"Garcia-Rodriguez LA, Gonzalez-Perez A, Stang MR, et al. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases. Pharmacoepidemiol Drug Saf. 2008;17(10):953\u201361.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"232_CR11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","volume":"17","author":"LA Garcia-Rodriguez","year":"2008","unstructured":"Garcia-Rodriguez LA, Masso-Gonzalez EL, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf. 2008;17(10):943\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"232_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21817","volume":"42","author":"BM Meador","year":"2010","unstructured":"\u2022 Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010;42(4):469\u201379. This is an important review on the relationship between exercise and statin myopathy.","journal-title":"Muscle Nerve"},{"issue":"1","key":"232_CR13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0317167100007630","volume":"35","author":"SK Baker","year":"2008","unstructured":"\u2022 Baker SK, Vladutiu GD, Peltier WL, et al. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci. 2008;35(1):94\u20137. This is an important report on metabolic myopathies unmasked by statin therapy.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"232_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/00498250802585539","volume":"39","author":"J Sidaway","year":"2009","unstructured":"Sidaway J, Wang Y, Marsden AM, et al. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica. 2009;39(1):90\u20138.","journal-title":"Xenobiotica"},{"issue":"1","key":"232_CR15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","volume":"28","author":"MA Silva","year":"2006","unstructured":"Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26\u201335.","journal-title":"Clin Ther"},{"issue":"6","key":"232_CR16","doi-asserted-by":"crossref","first-page":"e2522","DOI":"10.1371\/journal.pone.0002522","volume":"3","author":"M Molokhia","year":"2008","unstructured":"Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991 to 2006. PLoS One. 2008;3(6):e2522.","journal-title":"PLoS One"},{"issue":"4","key":"232_CR17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pds.1711","volume":"18","author":"C Rowan","year":"2009","unstructured":"Rowan C, Brinker AD, Nourjah P, et al. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(4):301\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"232_CR18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/mus.20135","volume":"30","author":"SK Baker","year":"2004","unstructured":"Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin to colchicine. Muscle Nerve. 2004;30(6):799\u2013802.","journal-title":"Muscle Nerve"},{"issue":"3","key":"232_CR19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2125.2009.03473.x","volume":"68","author":"J Strandell","year":"2009","unstructured":"Strandell J, Bate A, Hagg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"992","key":"232_CR20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/pgmj.2007.064097","volume":"84","author":"C O\u2019Mahony","year":"2008","unstructured":"O\u2019Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ. Rhabdomyolysis with atorvastatin and fusidic acid. Postgrad Med J. 2008;84(992):325\u20137.","journal-title":"Postgrad Med J"},{"issue":"4","key":"232_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CLC.2008.n.036","volume":"9","author":"M Veeraputhiran","year":"2008","unstructured":"Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer. 2008;9(4):232\u20134.","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"232_CR22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1464-5491.2008.02536.x","volume":"25","author":"DP Kao","year":"2008","unstructured":"Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25(10):1229\u201330.","journal-title":"Diabet Med"},{"issue":"15\u201316","key":"232_CR23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.lfs.2008.01.021","volume":"82","author":"R Dorajoo","year":"2008","unstructured":"Dorajoo R, Pereira BP, Yu Z, et al. Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy. Life Sci. 2008;82(15\u201316):823\u201330.","journal-title":"Life Sci"},{"issue":"2","key":"232_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1463-1326.2008.00917.x","volume":"11","author":"R Franssen","year":"2009","unstructured":"Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009;11(2):89\u201394.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"232_CR25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-140-8-200404200-00034","volume":"140","author":"R Fux","year":"2004","unstructured":"Fux R, Morike K, Gundel UF, et al. Ezetimibe and statin-associated myopathy. Ann Intern Med. 2004;140(8):671\u20132.","journal-title":"Ann Intern Med"},{"issue":"2","key":"232_CR26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","volume":"22","author":"C Simard","year":"2006","unstructured":"Simard C, Poirier P. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Can J Cardiol. 2006;22(2):141\u20134.","journal-title":"Can J Cardiol"},{"issue":"11","key":"232_CR27","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","volume":"101","author":"A Kashani","year":"2008","unstructured":"Kashani A, Sallam T, Bheemreddy S, et al. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101(11):1606\u201313.","journal-title":"Am J Cardiol"},{"issue":"6","key":"232_CR28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","volume":"20","author":"GD Vladutiu","year":"2008","unstructured":"Vladutiu GD. Genetic predisposition to statin myopathy. Curr Opin Rheumatol. 2008;20(6):648\u201355.","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"232_CR29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/gm120","volume":"1","author":"BJ Peters","year":"2009","unstructured":"Peters BJ, Klungel OH, Visseren FL, et al. Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Med. 2009;1(12):120.","journal-title":"Genome Med"},{"issue":"8","key":"232_CR30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"issue":"17","key":"232_CR31","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","volume":"54","author":"D Voora","year":"2009","unstructured":"\u2022 Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609\u201316. This is an important report showing that the SLCO1B1*5 polymorphism is a risk factor for statin myopathy.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"232_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/tpj.2009.3","volume":"9","author":"T Furihata","year":"2009","unstructured":"Furihata T, Satoh N, Ohishi T, et al. Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J. 2009;9(3):185\u201393.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"232_CR33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","volume":"210","author":"A Ghatak","year":"2010","unstructured":"\u2022 Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010;210(2):337\u201343. This is a comprehensive review on the role of genetic variants in predisposing to statin myopathy.","journal-title":"Atherosclerosis"},{"key":"232_CR34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","volume":"6","author":"J Oh","year":"2007","unstructured":"Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7.","journal-title":"Lipids Health Dis"},{"issue":"3","key":"232_CR35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","volume":"36","author":"G Ruano","year":"2007","unstructured":"Ruano G, Thompson PD, Windemuth A, et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve. 2007;36(3):329\u201335.","journal-title":"Muscle Nerve"},{"issue":"2","key":"232_CR36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","volume":"34","author":"GD Vladutiu","year":"2006","unstructured":"Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153\u201362.","journal-title":"Muscle Nerve"},{"issue":"6","key":"232_CR37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","volume":"39","author":"SK Tay","year":"2008","unstructured":"Tay SK, Dimauro S, Pang AY, et al. Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation. Pediatr Neurol. 2008;39(6):426\u20138.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"232_CR38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","volume":"57","author":"JE Thomas","year":"2007","unstructured":"Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol. 2007;57(4):232\u20135.","journal-title":"Eur Neurol"},{"issue":"1","key":"232_CR39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","volume":"109","author":"M Itagaki","year":"2009","unstructured":"\u2022 Itagaki M, Takaguri A, Kano S, et al. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci. 2009;109(1):94\u2013101. This is a comprehensive review of cellular mechanisms of statin myopathy.","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"232_CR40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2008.05.021","volume":"202","author":"C Vaklavas","year":"2009","unstructured":"Vaklavas C, Chatzizisis YS, Ziakas A, et al. Molecular basis of statin-associated myopathy. Atherosclerosis. 2009;202(1):18\u201328.","journal-title":"Atherosclerosis"},{"issue":"8","key":"232_CR41","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","volume":"79","author":"PJ Mullen","year":"2010","unstructured":"Mullen PJ, Luscher B, Scharnagl H, et al. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010;79(8):1200\u20139.","journal-title":"Biochem Pharmacol"},{"key":"232_CR42","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pone.0000097","volume":"1","author":"R Laaksonen","year":"2006","unstructured":"Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006;1:e97.","journal-title":"PLoS One"},{"issue":"1","key":"232_CR43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5551\/jat.E551","volume":"16","author":"JG Yu","year":"2009","unstructured":"Yu JG, Sewright K, Hubal MJ, et al. Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain. J Atheroscler Thromb. 2009;16(1):21\u20139.","journal-title":"J Atheroscler Thromb"},{"issue":"Pt 1","key":"232_CR44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","volume":"587","author":"JE Mallinson","year":"2009","unstructured":"\u2022 Mallinson JE, Constantin-Teodosiu D, Sidaway J, et al. Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol. 2009;587(Pt 1):219\u201330. This is an important experimental study of activation of muscle atrophy genes in statin myopathy.","journal-title":"J Physiol"},{"issue":"9","key":"232_CR45","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","volume":"23","author":"P Cao","year":"2009","unstructured":"Cao P, Hanai J, Tanksale P, et al. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 2009;23(9):2844\u201354.","journal-title":"FASEB J"},{"issue":"6","key":"232_CR46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","volume":"61","author":"T Rundek","year":"2004","unstructured":"Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004;61(6):889\u201392.","journal-title":"Arch Neurol"},{"issue":"11","key":"232_CR47","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","volume":"62","author":"C Lamperti","year":"2005","unstructured":"Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005;62(11):1709\u201312.","journal-title":"Arch Neurol"},{"issue":"6","key":"232_CR48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","volume":"19","author":"CF Schaars","year":"2008","unstructured":"Schaars CF, Stalenhoef AF. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol. 2008;19(6):553\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"232_CR49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5551\/jat.E812","volume":"16","author":"T Kohro","year":"2009","unstructured":"\u2022 Kohro T, Yamazaki T. Mechanism of statin-induced myopathy investigated using microarray technology. J Atheroscler Thromb. 2009;16(1):30\u20132. This is a gene expression study of statin myopathy.","journal-title":"J Atheroscler Thromb"},{"issue":"23","key":"232_CR50","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","volume":"49","author":"L Marcoff","year":"2007","unstructured":"Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"232_CR51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","volume":"153","author":"W Ahmed","year":"2009","unstructured":"Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32\u00a0ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009;153(1):11\u20136.","journal-title":"Transl Res"},{"issue":"1","key":"232_CR52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2265.2008.03448.x","volume":"71","author":"P Lee","year":"2009","unstructured":"Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency\u2013a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf). 2009;71(1):154\u20135.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"232_CR53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-7843.2006.pto_193.x","volume":"98","author":"K Soininen","year":"2006","unstructured":"Soininen K, Niemi M, Kilkki E, et al. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol. 2006;98(1):51\u20134.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"22","key":"232_CR54","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","volume":"165","author":"KE Hansen","year":"2005","unstructured":"Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671\u20136.","journal-title":"Arch Intern Med"},{"issue":"2","key":"232_CR55","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"\u2022 Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010;41(2):185\u201390. This is a report of a group of cases of immune-mediated necrotizing myopathy associated with statin therapy.","journal-title":"Muscle Nerve"},{"issue":"2","key":"232_CR56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","volume":"17","author":"M Needham","year":"2007","unstructured":"\u2022 Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194\u2013200. This is the first report of immune-mediated necrotizing myopathy associated with statins.","journal-title":"Neuromuscul Disord"},{"issue":"13","key":"232_CR57","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681\u201390.","journal-title":"JAMA"},{"issue":"8","key":"232_CR58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nmd.2007.04.001","volume":"17","author":"D Wahl","year":"2007","unstructured":"Wahl D, Petitpain N, Frederic M, et al. Myopathy associated with statin therapy. Neuromuscul Disord. 2007;17(8):661\u20132.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"232_CR59","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","volume":"362","author":"A Echaniz-Laguna","year":"2010","unstructured":"Echaniz-Laguna A, Mohr M, Tranchant C. Neuromuscular symptoms and elevated creatine kinase after statin withdrawal. N Engl J Med. 2010;362(6):564\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"232_CR60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","volume":"67","author":"L Sailler","year":"2008","unstructured":"Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis. 2008;67(5):614\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"232_CR61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.revmed.2003.10.013","volume":"25","author":"Al Fauchais","year":"2004","unstructured":"Fauchais Al, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne. 2004;25(4):294\u20138.","journal-title":"Rev Med Interne"},{"issue":"1","key":"232_CR62","first-page":"25","volume":"44","author":"A Takagi","year":"2004","unstructured":"Takagi A, Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku. 2004;44(1):25\u20137.","journal-title":"Rinsho Shinkeigaku"},{"issue":"10","key":"232_CR63","doi-asserted-by":"crossref","first-page":"934","DOI":"10.33588\/rn.3710.2003263","volume":"37","author":"G Riesco-Eizaguirre","year":"2003","unstructured":"Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use. Rev Neurol. 2003;37(10):934\u20136.","journal-title":"Rev Neurol"},{"issue":"9065","key":"232_CR64","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(05)61628-5","volume":"349","author":"N Giordano","year":"1997","unstructured":"Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet. 1997;349(9065):1600\u20131.","journal-title":"Lancet"},{"issue":"6","key":"232_CR65","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/14740338.2011.522441","volume":"9","author":"G Famularo","year":"2010","unstructured":"Famularo G, Minisola G, Gasbarrone L. Comment and reply on: atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link? Expert Opin Drug Saf. 2010;9(6):1005\u20136. author reply 6.","journal-title":"Expert Opin Drug Saf"},{"key":"232_CR66","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/rheumatology\/32.7.647","volume":"32","author":"F Khattak","year":"1993","unstructured":"Khattak F, Morris I, Branford W. Simvastatin-associated dermatomyositis. Br J Rheumatol. 1993;32:647\u20138.","journal-title":"Br J Rheumatol"},{"issue":"6","key":"232_CR67","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mus.20127","volume":"30","author":"OM Vasconcelos","year":"2004","unstructured":"Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve. 2004;30(6):803\u20137.","journal-title":"Muscle Nerve"},{"issue":"8","key":"232_CR68","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9343(01)00711-2","volume":"110","author":"B Noel","year":"2001","unstructured":"Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110(8):670\u20131.","journal-title":"Am J Med"},{"issue":"6","key":"232_CR69","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1445-5994.1995.tb02870.x","volume":"25","author":"C Hill","year":"1995","unstructured":"Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med. 1995;25(6):745\u20136.","journal-title":"Aust N Z J Med"},{"issue":"853","key":"232_CR70","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/pgmj.72.853.694","volume":"72","author":"JL Rodriguez-Garcia","year":"1996","unstructured":"Rodriguez-Garcia JL. Serrano Commino M: Lovastatin-associated dermatomyositis. Postgrad Med J. 1996;72(853):694.","journal-title":"Postgrad Med J"},{"issue":"11","key":"232_CR71","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.revmed.2005.07.005","volume":"26","author":"P Zuech","year":"2005","unstructured":"Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis. Rev Med Interne. 2005;26(11):897\u2013902.","journal-title":"Rev Med Interne"},{"issue":"12 Pt 1","key":"232_CR72","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/S0151-9638(05)79565-X","volume":"132","author":"N Thual","year":"2005","unstructured":"Thual N, Penven K, Chevallier JM, et al. Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol. 2005;132(12 Pt 1):996\u20139.","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"232_CR73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.nmd.2007.08.008","volume":"18","author":"D Hilton-Jones","year":"2008","unstructured":"Hilton-Jones D. Myopathy associated with statin therapy. Neuromuscul Disord. 2008;18(1):97\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"232_CR74","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"\u2022 Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321. This is the first report of antibodies to HMGCR in statin-associated necrotizing myopathy.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"232_CR75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337\u201345.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"232_CR76","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","volume":"63","author":"MS Cartwright","year":"2004","unstructured":"Cartwright MS, Jeffery DR, Nuss GR, Donofrio PD. Statin-associated exacerbation of myasthenia gravis. Neurology. 2004;63(11):2188.","journal-title":"Neurology"},{"issue":"2","key":"232_CR77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","volume":"85","author":"V Purvin","year":"2006","unstructured":"Purvin V, Kawasaki A, Smith KH, Kesler A. Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Medicine (Baltimore). 2006;85(2):82\u20135.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"232_CR78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","volume":"21","author":"B Noel","year":"2007","unstructured":"Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"232_CR79","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1756-185X.2010.01481.x","volume":"13","author":"D Sen","year":"2010","unstructured":"Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin\/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis. 2010;13(3):e29\u201331.","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"232_CR80","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1191\/0961203305lu2217oa","volume":"14","author":"P Riboldi","year":"2005","unstructured":"Riboldi P, Gerosa M, Meroni PL. Statins and autoimmune diseases. Lupus. 2005;14(9):765\u20138.","journal-title":"Lupus"},{"issue":"9425","key":"232_CR81","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(04)16423-4","volume":"363","author":"B Noel","year":"2004","unstructured":"Noel B. Autoimmune disease and other potential side-effects of statins. Lancet. 2004;363(9425):2000.","journal-title":"Lancet"},{"issue":"12","key":"232_CR82","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858\u201368.","journal-title":"Ann Intern Med"},{"issue":"4","key":"232_CR83","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11936-009-0027-3","volume":"11","author":"IW Smiley","year":"2009","unstructured":"Smiley IW, Khan BV, Sperling LS. Management of the statin-intolerant patient. Curr Treat Options Cardiovasc Med. 2009;11(4):263\u201371.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"6","key":"232_CR84","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/83.6.687","volume":"83","author":"TA Jacobson","year":"2008","unstructured":"Jacobson TA. Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83(6):687\u2013700.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"232_CR85","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","volume":"42","author":"JM Backes","year":"2008","unstructured":"Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42(3):341\u20136.","journal-title":"Ann Pharmacother"},{"issue":"16","key":"232_CR86","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM199004193221602","volume":"322","author":"MC Dalakas","year":"1990","unstructured":"Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990;322(16):1098\u2013105.","journal-title":"N Engl J Med"},{"issue":"6","key":"232_CR87","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","volume":"49","author":"JI Seok","year":"2009","unstructured":"\u2022 Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009;49(6):2080\u20136. This is the first report of mitochondrial myopathy due to clevudine.","journal-title":"Hepatology"},{"issue":"1","key":"232_CR88","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1212\/WNL.0b013e3181aae814","volume":"73","author":"G Pfeffer","year":"2009","unstructured":"Pfeffer G, Cote HC, Montaner JS, et al. Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology. 2009;73(1):71\u20132.","journal-title":"Neurology"},{"issue":"2","key":"232_CR89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/01480540903207076","volume":"33","author":"J Finsterer","year":"2010","unstructured":"Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol. 2010;33(2):138\u201351.","journal-title":"Drug Chem Toxicol"},{"issue":"4","key":"232_CR90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1445-5994.1995.tb01912.x","volume":"25","author":"JD England","year":"1995","unstructured":"England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors\u2013simvastatin and pravastatin. Aust N Z J Med. 1995;25(4):374\u20135.","journal-title":"Aust N Z J Med"},{"issue":"7","key":"232_CR91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","volume":"137","author":"PS Phillips","year":"2002","unstructured":"Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137(7):581\u20135.","journal-title":"Ann Intern Med"},{"issue":"4","key":"232_CR92","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2125.2008.03224.x","volume":"66","author":"F Lapi","year":"2008","unstructured":"Lapi F, Gallo E, Bernasconi S, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol. 2008;66(4):572\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"232_CR93","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/00007890-200210270-00028","volume":"74","author":"GV Prasad","year":"2002","unstructured":"Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74(8):1200\u20131.","journal-title":"Transplantation"},{"issue":"11","key":"232_CR94","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1056\/NEJMoa010581","volume":"345","author":"R Bedry","year":"2001","unstructured":"Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med. 2001;345(11):798\u2013802.","journal-title":"N Engl J Med"},{"issue":"2","key":"232_CR95","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/153537020623100213","volume":"231","author":"P Nieminen","year":"2006","unstructured":"Nieminen P, Kirsi M, Mustonen AM. Suspected myotoxicity of edible wild mushrooms. Exp Biol Med (Maywood). 2006;231(2):221\u20138.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7","key":"232_CR96","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nchembio.179","volume":"5","author":"M Matsuura","year":"2009","unstructured":"Matsuura M, Saikawa Y, Inui K, et al. Identification of the toxic trigger in mushroom poisoning. Nat Chem Biol. 2009;5(7):465\u20137.","journal-title":"Nat Chem Biol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0232-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-011-0232-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0232-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T10:35:57Z","timestamp":1741775757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-011-0232-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,4]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s11910-011-0232-9","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,4]]}}}